Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CART2219.1
- Development stage
- Unknown
- Lead developer
- KK Women's and Children's Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CART2219.1 is an autologous dual-targeting chimeric antigen receptor (CAR) T-cell therapy developed by KK Women's and Children's Hospital. It is engineered to express CARs that simultaneously target two distinct B-cell antigens, CD19 and CD22. This dual-targeting strategy is designed to enhance therapeutic efficacy and mitigate the risk of leukemia relapse caused by antigen loss or "escape," which is a common resistance mechanism in single-target CAR-T therapies. CART2219.1 is currently being evaluated in clinical trials as a salvage treatment for pediatric and adult patients with relapsed or refractory B-lineage acute lymphoblastic leukemia (B-ALL), potentially offering an alternative to intensive treatments like hematopoietic stem cell transplantation or total body irradiation.
- Other names
- Dual Anti-CD22/CD19 CAR-T cellsCART2219.1-KKHCART-2219.1-KKHCART 2219.1-KKH
02
Targets
CD19 (B lymphocyte antigen CD19)CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on CART2219.1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CART2219.1.